Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer Interventions: Drug: CA102N; Drug: TAS-102; Biological: Bevacizumab Sponsor: Holy Stone Healthcare Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials